Metformin Actavis

Metformin, the active ingredient in Metformin Actavis, is a biguanide presented as an oral dosage form for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus. It is indicated as part of a comprehensive diabetes management program that includes diet, exercise and other antihyperglycemic agents when appropriate.

GNH USA supplies Metformin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Metformin Actavis is used in the management of disorders related to impaired glucose metabolism, primarily type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial blood glucose levels. - Type 2 diabetes mellitus (adjunct to diet and exercise): enhances overall glycemic control when lifestyle measures alone are insufficient. - Type 2 diabetes mellitus (combination therapy): provides additive glucose‑lowering effect when used with other antihyperglycemic agents such as sulfonylureas or insulin.

Metformin may cause a range of adverse reactions, most of which are related to the gastrointestinal tract, while rare events can be serious.

Common Side Effects: - Nausea: mild to moderate discomfort often occurring after the first doses. - Diarrhea: loose stools that may improve with continued therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: gradual decrease detectable with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal accumulation of lactate. - Severe hypoglycemia: usually when combined with insulin or sulfonylureas. - Hepatic dysfunction: abnormal liver enzymes indicating liver injury. - Skin rash or hypersensitivity: including Stevens‑Johnson syndrome. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Renal impairment worsening: decline in kidney function due to accumulation of the drug.

Before initiating Metformin Actavis, several safety considerations should be reviewed.

- Renal function assessment: evaluate creatinine clearance to ensure adequate excretion. - Hepatic function monitoring: avoid use in patients with significant liver disease. - Contraindication in severe renal impairment: do not use if eGFR <30 mL/min/1.73 m². - Alcohol consumption: limit intake to reduce risk of lactic acidosis. - Elderly dosing: consider lower starting dose and titrate cautiously. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Actavis can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Trimethoprim: may reduce renal clearance of metformin.

Moderate Interactions (Monitor Closely): - Beta‑blockers: can mask hypoglycemia symptoms. - Diuretics (especially thiazides): may affect renal function and electrolyte balance. - ACE inhibitors or ARBs: monitor renal function and potassium levels when used together.